All of this is to say, patients and physicians are being driven to GLP-1s, particularly semaglutide, for managing obesity
Semi-quantitative analysis was performed for five fields per section in high-power fields at 400 magnification using ImageJ software version 64 (National Institutes of Health)
Neurosci Lett 817:137518 Zong Y, Chen F, Li S, Zhang H (2021) ()-Epigallocatechin-3-gallate (EGCG) prevents aminoglycosides-induced ototoxicity via anti-oxidative and anti-apoptotic pathways
The arrival of the GLP-1 receptor agonists, especially Wegovy, marked an inflection point for the obesity market, because for the first time pharmacological interventions delivered meaningful weight loss of 10-15%
This holistic approach significantly increases the likelihood of achieving and sustaining weight loss compared to generic methods
Many patients find that 1224 months on medication provides enough time to build new eating habits that persist even if they eventually discontinuethough continued treatment remains the best strategy to prevent regain